| Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Scandinavian Simvastatin Survival Study Group The Lancet 344 (8934), 1383-1389, 1994 | 11058 | 1994 |
| Physiology of penile erection KE Andersson, G Wagner Physiological reviews 75 (1), 191-236, 1995 | 1611 | 1995 |
| Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ … P Abrams, KE Andersson, L Birder, L Brubaker, L Cardozo, C Chapple, ... Neurourol Urodyn 29 (1), 213-40, 2010 | 1572 | 2010 |
| Urinary bladder contraction and relaxation: physiology and pathophysiology KE Andersson, A Arner Physiological reviews 84 (3), 935-986, 2004 | 1307 | 2004 |
| Pharmacology of the lower urinary tract KE Andersson, C Gratzke Textbook of the neurogenic bladder, 95-114, 2008 | 1026 | 2008 |
| Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder P Abrams, KE Andersson, JJ Buccafusco, C Chapple, WC De Groat, ... British journal of pharmacology 148 (5), 565-578, 2006 | 744 | 2006 |
| Pharmacology of penile erection KE Andersson Pharmacological reviews 53 (3), 417-450, 2001 | 717 | 2001 |
| Defective smooth muscle regulation in cGMP kinase I‐deficient mice A Pfeifer, P Klatt, S Massberg, L Ny, M Sausbier, C Hirneiß, GX Wang, ... The EMBO journal, 1998 | 670 | 1998 |
| EAU guidelines on urinary incontinence JW Thüroff, P Abrams, KE Andersson, W Artibani, CR Chapple, MJ Drake, ... Actas Urológicas Españolas (English Edition) 35 (7), 373-388, 2011 | 658 | 2011 |
| Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence KE Andersson, AJ Wein Pharmacological reviews 56 (4), 581-631, 2004 | 612 | 2004 |
| The pharmacological treatment of urinary incontinence KE Andersson, R Appell, LD Cardozo, C Chapple, HP Drutz, ... BJU international 84, 923-947, 1999 | 605 | 1999 |
| Antimuscarinics for treatment of overactive bladder KE Andersson The Lancet Neurology 3 (1), 46-53, 2004 | 582 | 2004 |
| Anatomy, physiology, and pathophysiology of erectile dysfunction C Gratzke, J Angulo, K Chitaley, Y Dai, NN Kim, JS Paick, U Simonsen, ... The journal of sexual medicine 7 (1_Part_2), 445-475, 2010 | 566 | 2010 |
| Summary of the recommendations on sexual dysfunctions in men TF Lue, F Giuliano, F Montorsi, RC Rosen, KE Andersson, S Althof, ... The journal of sexual medicine 1 (1), 6-23, 2004 | 560 | 2004 |
| Urothelial signaling L Birder, KE Andersson Physiological reviews 93 (2), 653-680, 2013 | 545 | 2013 |
| Muscarinic receptor antagonists for overactive bladder P Abrams, KE Andersson BJU international 100 (5), 987-1006, 2007 | 525 | 2007 |
| Bladder activation: afferent mechanisms KE Andersson Urology 59 (5), 43-50, 2002 | 511 | 2002 |
| Summary of the recommendations on sexual dysfunctions in men F Montorsi, G Adaikan, E Becher, F Giuliano, S Khoury, TF Lue, I Sharlip, ... The journal of sexual medicine 7 (11), 3572-3588, 2010 | 486 | 2010 |
| Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction KE Andersson Pharmacological reviews 63 (4), 811-859, 2011 | 477 | 2011 |
| The vasodilator‐stimulated phosphoprotein (VASP) is involved in cGMP‐and cAMP‐mediated inhibition of agonist‐induced platelet aggregation, but is dispensable for smooth muscle … A Aszodi, A Pfeifer, M Ahmad, M Glauner, XH Zhou, L Ny, KE Andersson, ... The EMBO journal, 1999 | 454 | 1999 |